- Recommendation ID
- TA319/1
- Question
- NICE considered that more research is needed to establish the treatment sequence for vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma.
- Any explanatory notes
(if applicable) - This may provide important information about patient subgroups that should be targeted with the different treatments first-line. NICE was aware that several trials were ongoing that explored treatment sequences relating to vemurafenib and ipilimumab and considered that these would be important. NICE encouraged patient recruitment to these trials.
Source guidance details
- Comes from guidance
- Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
- Number
- TA319
- Date issued
- July 2014
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 07/10/2014 |